Achieving Treatment Goals in Inflammatory Bowel Disease: The Role of Gut-Selective Therapy

Summary of presentations from the Takeda-sponsored symposia held at the 23rd United European Gastroenterology Week in Barcelona, Spain, on 26th and 28th October 2015

Gut-Selective Biologic Therapy for Ulcerative Colitis: Lessons from Science and Practice
Chairperson: Gert Van Assche1
Speakers: Axel U. Dignass,2 Britta Siegmund,3 William J. Sandborn4

Management of Crohn’s Disease: Current Concepts, Future Directions 
Chairperson: Laurent Peyrin-Biroulet5
Speakers: James O. Lindsay,6 Iris Dotan7

1. University of Leuven, Leuven, Belgium
2. Agaplesion Markus Hospital, Goethe University, Frankfurt, Germany
3. Charité-Universitätsmedizin Berlin, Berlin, Germany
4. Inflammatory Bowel Disease Center, UC San Diego Health System, La Jolla, California, USA
5. Nancy University Hospital, Vandœuvre-lès-Nancy, France
6. Barts Health NHS Trust and Queen Mary University of London, London, UK
7. Tel Aviv Sourasky Medical Center, The Sackler School of Medicine, Tel Aviv, Israel

Disclosure: Gert Van Assche has received honoraria/consultancy fees from AbbVie, Takeda, Ferring, Merck Sharp and Dohme, Janssen Pharmaceuticals, and Pfizer. Axel Dignass has served as a consultant for Abbvie, MSD, Ferring, Roche/Genentech, Takeda, Pharmacosmos, Holystone Biotech, Falk Foundation, Mundipharma, Toray, Allergosan, Hospira, Robarts, TFS Trial Support, and Sandoz/Hexal; has received honoraria for lectures and participation in speakers’ bureaux for Ferring, Falk Foundation, MSD, Abbvie, Otsuka, Vifor, Immundiagnostik, Jansen-Cilag, Med Update GmbH, Medice, CED Service GmbH, and Mundipharma; has received honoraria for development of educational presentations for Pharmacosmos and Falk Foundation; has received honoraria for manuscript preparation from Wiley, Thieme, Allergosan, and Falk Foundation; has received grants to his institution from the Institut für Gemeinwohl and Stiftung Leben mit Krebs; and has received payment for travel to meetings and received administrative support from the European Cancer Organisation. Britta Siegmund has received advisory board and speaking honoraria from Takeda. William J. Sandborn has received research funding and consultancy fees from Takeda. James O. Lindsay has received speaker honoraria, advisory board fees, and sponsorship to attend academic meetings from Takeda, Hospira, Merck Sharpe and Dohme, AbbVie, and Napp, and research funding from Takeda and Hospira. Iris Dotan has received speaking and teaching support from Takeda, Janssen, AbbVie, Ferring, Falk Pharma, and Given Imaging Advisory boards, and has provided consultation to Takeda, Janssen, AbbVie, Ferring, Rafa Laboratories, Given Imaging, Protalix, Genentech, and Pfizer. Laurent Peyrin-Biroulet has received consulting fees from Merck, Abbvie, Janssen, Genentech, Mitsubishi, Ferring, Norgine, Tillots, Vifor, Therakos, Pharmacosmos, Pilège, BMS, UCB Pharma, Hospira, Celltrion, Takeda, Biogaran, Boehringer Ingelheim, Lilly, Pfizer, HAC Pharma, Index Pharmaceuticals, Amgen, Sandoz, and Forward Pharma GmbH. He has also received lecture fees from Merck, Abbvie, Takeda, Janssen, Takeda, Ferring, Norgine, Tillots, Vifor, Therakos, Mitsubishi, and HAC Pharma.
Acknowledgements: Writing assistance was provided by Dr Lauri Arnstein, Ashfield Healthcare Communications Ltd.
Support: The publication of this article was funded by Takeda. The views and opinions expressed are those of the speakers and not necessarily of Takeda.
Citation: EMJ Gastroenterol. 2015;4[1]:40-49.

Meeting Summary

Despite major advances in the inflammatory bowel disease (IBD) treatment landscape, the management of ulcerative colitis (UC) and Crohn’s disease (CD) continues to pose challenges. There is significant scope to optimise treatment of IBD, and conventional therapies may fail to meet evolving treatment goals. Induction of remission with clinical control of symptoms and maintenance of remission with long-term prevention of disease progression are important considerations for healthcare professionals. The concept of complete remission integrates clinical remission, patient-reported outcomes, and mucosal healing, a key therapeutic goal for disease modification. The anti-integrin vedolizumab has been proven to be effective in inducing and maintaining clinical remission in IBD, both first-line and in tumour necrosis factor α (TNFα)-experienced patients, and has demonstrated mucosal healing benefits in UC patients. Safety remains critical for all therapies and vedolizumab is generally well-tolerated across all age groups, including the elderly. Real-world experience with vedolizumab has shown broadly comparable outcomes to the pivotal clinical trials.

Click here to view full webcast.

Download (PDF, 532KB)

Comments are closed.